Ashar Bhavesh 4
4 · SpringWorks Therapeutics, Inc. · Filed Feb 5, 2024
Insider Transaction Report
Form 4
Ashar Bhavesh
Chief Commercial Officer
Transactions
- Sale
Common Stock
2024-02-02$43.75/sh−1,089$47,640→ 65,121 total - Sale
Common Stock
2024-02-02$46.00/sh−378$17,387→ 63,076 total - Sale
Common Stock
2024-02-02$44.31/sh−1,667$73,868→ 63,454 total - Sale
Common Stock
2024-02-02$46.37/sh−88$4,081→ 62,988 total - Sale
Common Stock
2024-02-05$49.32/sh−4,834$238,435→ 58,154 total
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on December 16, 2022.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.05 to $44.035. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.05 to $44.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.29 to $46.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.29 to $47.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.